drugset / Trial / NCT03299166
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
Timeline
- Start
- 2017-12-19
- Primary completion
- 2020-06-02
- Completion
- 2025-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Troriluzole | Peptide | 200 mg | Oral |